Список литературы

1. Аббасова, С.Г. Онкологические заболевания и растворимый Fas / С. Г. Аббасова [и др.] // Бюл. эксперимент. биологии и медицины. – 2009. – T. 148,

№10. – С. 442-446.

2. Барсуков, А.В.

3. Бацков, С.С. Ультразвуковой метод исследования в гастроэнтерологии / С.С. Бацков. – СПб.: Основа, 1995. – 182 с.

4. Бримкулов, Н.Н. Применение опросника SF-36 для оценки качества жизни / Н.Н. Бримкулов, Н.Ю. Сенкевич, А.Д. Калиева // Центральноазиат. мед. журн. – 1998. – №4-5. – С. 236-241.

5. Бритвин, T.А. Адренокортикальный рак (современное состояние проблемы) / T.А. Бритвин, А.П. Калинин, Д.А. Пирогов // Сибир. мед. журн. (Иркутск). – 2008. – T. 81, №6. – С. 13-19.

6. Бритвин, T.А. Диагностика и лечение адренокортикального рака : пособие для врачей / T.А. Бритвин. – М.: Моники, 2008. – 23 с.

7. Бритвин, T.А. Исследование уровней растворимого Fas-антигена при опухолях надпочечников / T.А. Бритвин // Анналы хирургии. – 2004. – №5. – С. 65-68.

8. Бритвин, T.А. Опухоли надпочечников и интерлейкин-6 / T.А. Бритвин [и др.] // Клин. лаборатор. диагностика. – 2004. – №9. – С. 7а-7.

9. Бритвин, T.А. Сосудистый эвдотелиальный фактор роста (VEGF) у больных опухолями коры надпочечников / T.А. Бритвин, Н.Е. Кушлинский, А.П. Калинин // Рос. биотерапевтич. журн. – 2004. – T. 3, №2. – С. 63.

10. Великанова, Л.И. Диагностическое значение ВЭЖХ кортикостероидов при различных патологиях системы гипофиз – кора надпочечников / Л. И. Великанова [и др.] // Клин. лаборатор. диагностика. – 2001. – №10. – C. 34-35.

11. Ветшев, П.С. Оценка методов диагностики новообразований надпочечников / П.С. Ветшев, Л.И. Ипполитов, T.И. Коваленко // Хирургия. – 2002. – №1. – С. 62-67.

12. Давыдов, М.И. Первичные и метастатические опухоли надпочечников : доклад / М.И.

13. Двойрин, В.В. Методика контролируемых клинических испытаний / В.В. Двойрин, А.А. Клименков. – М.: Медицина, 1985. – 143 с.

14. Дедов, И.И. Клиника и диагностика эндокринных нарушений / И.И. Дедов, Г.А. Мельниченко, В.В. Фадеев. – Тверь: Триада, 2005. – 248 c.

15. Довганюк, В.С. Современные технологии в диагностике и хирургическом лечении новообразований надпочечников : автореф. дис. … д-ра мед. наук :

14.00.27 / Виталий Сафронович Довганюк. – СПб, 2005. – 34 с.

16. Казанцева, И.А. Клиническая морфология кортикальных опухолей и гиперплазии надпочечников : пособие для врачей / И.А. Казанцева [и др.]. – М.: Моники, 1998. – 35 с.

17. Калашников, С.А. Эмбриология, анатомия, топография и функциональная морфология надпочечников / С.А. Калашников, П.Н. Ромащенко // Хирургическая эндокринология : руководство / под ред. Н.А. Майстренко. – СПб.: Питер, 2004. – С. 465-485.

18. Комиссаренко, И.В. Хирургическое лечение злокачественных опухолей надпочечных желез / И.В. Комиссаренко, С.И. Рыбаков, А.Н. Кваченюк // Хірургія України. – 2005. – T. 13, №1. – С. 53-57. – укр., рез. рус.

19. Котляров, П.М. Адренокортикальный рак надпочечника / П.М. Котляров [и др.] // Вестн. рос. науч. центра рентгенорадиологии Минздрава России. – 2011. – T. 2, №11. – С. 23.

20. Леонард, Д. Эндокринология / Д. Леонард, М.Х. Албоцта // Клиническая оценка лабораторных тестов: пер. с англ. / под ред. Н.У. Тица. – М.: Медицина, 1986. – С. 167-186.

21. Лучевая диагностика и лучевая терапия : учебное пособие / под ред. Г.Е. Труфанова. – СПб.: ВМедА, 2005. – 344 с.

22. Майстренко, Н.А. Новообразования надпочечников / Н.А. Майстренко [и др.]. – М.: Медпрактика-М, 2003. – 196 с.

23. Майстренко, Н.А. Опухоли надпочечников / Н.А. Майстренко // Клиническая хирургия : национальное руководство : в 3 т. / под ред. В.С. Савельева, А.И. Кириенко. – М.: ГЭОТАР-медиа, 2009. – Том II. – С. 53-94.

24. Майстренко, Н.А. Современные аспекты хирургии надпочечников / Н.А. Майстренко [и др.] // Хирургия. – 2000. – №5. – С. 30-32.

25. Математико-статистические методы в клинической практике : учебное пособие / под ред. В.И. Кувакина. – СПб.: ВМедА, 1993. – 200 с.

26. Мельниченко, Г.А. Лабораторная диагностика надпочечниковой недостаточности / Г.А. Мельниченко, В.В. Фадеев // Проблемы эндокринологии. – 1997. – T. 43, №5. – С. 39-47.

27. Мельниченко, Г.А. Проект российских клинических рекомендаций по диагностике и лечению адренокортикального рака / Г.А. Мельниченко [и др.] // Эндокрин. хирургия. – 2014. – №1. – С. 4-26.

28. Мельниченко, Г.А. Федеральные клинические рекомендации по диагностике и лечению адренокортикального рака / Г.А. Мельниченко [и др.] // Проблемы эндокринологии. – 2014. – T. 60, №2. – С. 51-67.

29. Молашенко, Н.В. Объемные образования надпочечников (диагностика и дифференциальная диагностика) / Н.В. Молашенко [и др.] // Проблемы эндокринологии. – 2010. – T. 56, №1. – С. 48-56.

30. Нечай, А.И. Неотложная супрареналтомия при феохромоцитоме / А.И. Нечай, В.М. Трофимов, Л.М. Краснов // Вестн. хирургии. – 1988. – T. 140. – С. 49-52.

31. Нечай, А.Л. Оценка гемодинамики с использованием интегральной реотрафии тела у больных с заболеваниями надпочечников : отчет НИР ВМедА 1988 / А.Л. Нечай, В.М. Трофимов, А.Г. Вавилов. – Л.: ВМедА, 1988. – 38 с.

32. Новик, А.А. Руководство по исследованию качества жизни в медицине / А.А. Новик, T.И. Ионова. – СПб.: Нева, 2002. – 320 с.

33. Патютко, Ю.И. Успешное хирургическое лечение рака надпочечника с неоднократным метастазированием / Ю.И. Патютко, А.Д. Гахраманов // Хирургия. Журн. им. Пирогова. – 2008. – №12. – С. 51-53.

34. Пирс, Э. Гистохимия теоретическая и прикладная / Э. Пирс. – М.: Иностранная литература, 1962. – 962 с.

35. Портной, Л.М. Лучевая диагностика заболеваний поджелудочной железы

/ Л.М. Портной, А.В. Араблинский // Рос. журн. гастроэнтерологии, гепатологии, колопроктологии.

36. Правосудов, В.В. Дифференциальная лучевая диагностика опухолей надпочечников / В.В. Правосудов [и др.] // Материалы Невского радиологического форума: из будущего в настоящее. – СПб.: [б.и.], 2003. – С. 217- 219.

37. Пчелин, И.Г. Спиральная компьютерная томография в диагностике опухолей надпочечников / И.Г. Пчелин, В.Д. Фадеев, В.В. Правосудов // Спиральная компьютерная томография технология XXI века : материалы научной конференции. – СПб.: ВМедА, 1998. – С. 27-29.

38. Райкин Н.Т. Иммуногистохимическая идентификация гормонально- неактивных опухолей надпочечников / Н.Т. Райкин [и др.] // Вопр. онкологии. – 2002. – T. 48, №6. – С. 684-690.

39. Тищенко, М.И. Характеристика и клиническое применение интегральной реографии – нового метода измерения ударного объема / М.И. Тищенко [и др.]

// Кардиология. – 1973. – №11. – C. 54-62.

40. Трапезникова, М.Ф. Метастазы опухоли почки в надпочечниках / М. Ф. Трапезникова [и др.] // Урология. – 2004. – №1. – С. 25-29.

41. Трофимов, В.М. Хирургическое лечение больных с гиперкортизолизмом (синдромом Иценко-Кушинга) при различных морфологических изменениях в надпочечниках : автореф. дис. … д-ра. мед. наук / Владислав Михайлович Трофимов. – М., 1986. – 34 с.

42. Филимонюк, А.В. Анатомо-топографические обоснования выбора хирургического доступа к надпочечникам при адренокортикальном раке [Электронный ресурс] / А.В. Филимонюк [и др.] // Вестн. новых мед. технологий : Электрон. изд. – 2013. – №1. – С. 69. – Режим доступа: http://www.medtsu.tula.ru/VNMT/Bulletin/E2013-1/4285.pdf – (Дата обращения: 27.10.2014).

43. Харнас С.С. Диагностика и лечение адренокортикального рака / С.С. Харнас [и др.] // Сечен. вестн. – 2013. – №2 (12). – С. 27-32.

44. Хирургия надпочечников / под ред. А.П.Калинина, Н.А.Майстренко. – М.: Медицина, 2000. – 216 с.

45. Цыб, А.Ф. Тонкоигольная биопсия под ультразвуковым наведением в диагностике опухолей органов малого таза / А.Ф. Цыб, Г.В. Нестайко, Г.Н. Гришин // Мед.

46. Черемисин, В.М. КТ в диагностике туберкулеза органов дыхания / В.М. Черемисин, И.Е. Тюрин // Воен.-мед. журн. – 1996. – №7. – С. 40-47.

47. Щетинин, В.В. Ультразвуковая оценка состояния печени и печеночного кровообращения у рабочих химического производства / В.В. Щетинин [и др.] // Эхография. – 2002. – №4. – С. 428-431.

48. Abiven, G. Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients / G. Abiven [et al.] // J. Clin. Endocrinol. Metab. – 2006. – Vol. 91, №7. – P. 2650-2655.

49. Abraham, J. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P- glycoprotein antagonist / J. Abraham [et al.] // Cancer. – 2002. – Vol. 94, №9. – P. 2333-2343.

50. Al-Hawary, M.M. Non-invasive evaluation of the incidentally detected indeterminate adrenal mass / M.M. Al-Hawary, I.R. Francis, M. Korobkin // Best Pract. Res. Clin. Endocrinol. Metab. – 2005. – Vol. 19, №2. – P. 277-292.

51. Allolio, B. Management of adrenocortical carcinoma / B. Allolio [et al.] // Clin. Endocrinol. (Oxf). – 2004. – Vol. 60, №3. – P. 273-287.

52. Assie, G. Gene expression profiling in adrenocortical neoplasia / G. Assie, T.

J. Giordano, J. Bertherat // Mol. Cell. Endocrinol. – 2012. – Vol. 351, №1. – P. 111- 117.

53. Assie, G. Prognostic parameters of metastatic adrenocortical carcinoma / G. Assie [et al.] // J. Clin. Endocrinol. Metab. – 2007. – Vol. 92, №1. – P. 148-154.

54. Aubert, S. Weiss system revisited: a clinicopathologic and immunohistochemical study of 49 adrenocortical tumors / S. Aubert [et al.] // Am. J. Surg. Pathol. – 2002. – Vol. 26, №12. – P. 1612-1619.

55. Ayala-Ramirez, M. Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center / M.

56. Bargenstal, D.M. Chemotherapy of adrenocortical cancer with p,p’DDD /

D.M. Bargenstal [et al.] // Ann. Intern. Med. – 1960. – Vol. 53. – P. 672-682.

57. Barzon, L. Adrenocortical carcinoma: experience in 45 patients / L. Barzon [et al.] // Oncology. – 1997. – Vol. 54, №6. – P. 490-496.

58. Bauditz, J. Improved detection of hepatic metastases of adrenocortical cancer by contrast-enhanced ultrasound / J. Bauditz [et al.] // Oncol. Rep. – 2008. – Vol. 19,

№5. – P. 1135-1139.

59. Bellantone, R. Role of reoperation in recurrence of adrenal cortical carcinoma: results from 188 cases collected in the Italian National Registry for Adrenal Cortical Carcinoma / R. Bellantone [et al.] // Surgery. – 1997. – Vol. 122, №6. – P. 1212- 1218.

60. Berruti, A. Emerging drugs for adrenocortical carcinoma / A. Berruti [et al.] // Expert Opin. Emerg. Drugs. – 2008. – Vol. 13, №3. – P. 497-509.

61. Berruti, A. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial / A. Berruti [et al.] // Endocr. Relat. Cancer. – 2005. – Vol. 12, №3. – P. 657-666.

62. Berruti, A. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer / A. Berruti [et al.] // Cancer. – 1998. – Vol. 83, №10. – P. 2194- 2200.

63. Bertherat, J. Adjuvant mitotane in adrenocortical carcinoma / J. Bertherat, J. Coste, X. Bertagna // N. Engl. J. Med. – 2007. – Vol. 357, №12. – P. 1256-1257; author reply P. 1259с.

64. Bertherat, J. Molecular and functional analysis of PRKAR1A and its locus (17q22-24) in sporadic adrenocortical tumors: 17q losses, somatic mutations, and protein kinase A expression and activity / J. Bertherat [et al.] // Cancer Res. – 2003. – Vol. 63, №17. – P. 5308-5319.

65. Bharwani, N. Adrenocortical carcinoma: the range of appearances on CT and MRI / N. Bharwani [et al.] // AJR. Am. J. Roentgenol. – 2011. – Vol. 196, №6. – P. 706-714.

66. Bilimoria, K.Y. Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors / K.Y. Bilimoria [et al.] // Cancer. – 2008. – Vol. 113, №11. – P. 3130-3136.

67. Boland, G.W. Characterization of adrenal masses using unenhanced CT: an analysis of the CT literature / G.W. Boland [et al.] // AJR. Am. J. Roentgenol. – 1998. – Vol. 171, №1. – P. 201-204.

68. Bonacci, R. Cytotoxic therapy with etoposide and cisplatin in advanced adrenocortical carcinoma / R. Bonacci [et al.] // Br. J. Cancer. – 1998. – Vol. 78, №4.

– P. 546-549.

69. Boulle, N. Increased levels of insulin-like growth factor II (IGF-II) and IGF- binding protein-2 are associated with malignancy in sporadic adrenocortical tumors /

N. Boulle [et al.] // J. Clin. Endocrinol. Metab. – 1998. – Vol. 83, №5. – P. 1713- 1720.

70. Brix, D. Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients / D. Brix [et al.] // Eur. Urol. – 2010. – Vol. 58, №4. – P. 609-615.

71. Brodsky, S.V. Vascular density and VEGF expression in hepatic lesions / S.V. Brodsky [et al.] // J. Gastrointestin. Liver Dis. – 2007. – Vol. 16, №4. – P. 373-277.

72. Brown, D.B. Concepts, considerations, and concerns on the cutting edge of radiofrequency ablation / D.B. Brown // J. Vasc. Interv. Radiol. – 2005. – Vol. 16,

№5. – P. 597-613.

73. Brown, D.B. Hepatic arterial chemoembolization for hepatocellular carcinoma: comparison of survival rates with different embolic agents / D.B. Brown [et al.] // J. Vasc. Interv. Radiol. – 2005. – Vol. 16, №12. – P. 1661-1666.

74. Bukowski, R.M. Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: a Southwest Oncology Group study / R.M. Bukowski [et al.] // J. Clin. Oncol. – 1993. – Vol. 11, №1. – P. 161-165.

75. Burgess, M.A. Mitotane failure in adrenocortical cancer: where next? / M.A. Burgess, S.S. Legha // Cancer. – 1993. – Vol. 72, №7. – P. 2293.

76. Carnaille, B. Adrenocortical carcinoma: which surgical approach? / B. Carnaille // Langenbecks. Arch. Surg. – 2012. – Vol. 397, №2. – P. 195-199.

77. Chacon R. Case 2. Response in a patient with metastatic adrenal cortical carcinoma with thalidomide / R. Chacon [et al.] // J. Clin. Oncol. – 2005. – Vol. 23,

№7. – 1579-1580.

78. Chow, W.H. Smoking and adrenal cancer mortality among United States veterans / W.H. Chow [et al.] // Cancer Epidemiol. Biomarkers Prev. – 1996. – Vol. 5, №2. – P. 79-80.

79. Costa, R. Chemotherapy for advanced adrenal cancer: improvement from a molecular approach? / R. Costa, R. Wesolowski, D. Raghavan // BJU Int. – 2011. – Vol. 108, №10. – P. 1546-1554.

80. Crucitti, F. The Italian Registry for Adrenal Cortical Carcinoma: analysis of a multiinstitutional series of 129 patients. The ACC Italian Registry Study Group / F. Crucitti [et al.] // Surgery. – 1996. – Vol. 119, №2. – P. 161-170.

81. Custodio, G. Molecular epidemiology of adrenocortical tumors in southern Brazil / G. Custodio [et al.] // Mol. Cell. Endocrinol. – 2012. – Vol. 351, №1. – P. 44- 51.

82. Dackiw, A.P. Adrenal cortical carcinoma / A.P. Dackiw [et al.] // World J. Surg. – 2001. – Vol. 25, №7. – P. 914-926.

83. de Baere, T. Radiofrequency ablation of lung and bone tumors / T. de Baere // Cancer Radiother. – 2006. – Vol. 10, №6-7. – P. 430-436.

84. de Fraipont, F. Expression of the angiogenesis markers vascular endothelial growth factor-A, thrombospondin-1, and platelet-derived endothelial cell growth factor in human sporadic adrenocortical tumors: correlation with genotypic alterations / F. de Fraipont [et al.] // J. Clin. Endocrinol. Metab. – 2000. – Vol. 85,

№12. – P. 4734-4741.

85. de Fraipont, F. Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic Acid microarrays identifies several candidate genes as markers of malignancy / F. de Fraipont [et al.] // J. Clin. Endocrinol. Metab.

– 2005. – Vol. 90, №3. – P. 1819-1829.

86. Dean, M. Tumour stem cells and drug resistance / M. Dean, T. Fojo, S. Bates // Nat. Rev. Cancer. – 2005. – Vol. 5, №4. – P. 275-284.

87. Decker, R.A. Eastern Cooperative Oncology Group study 1879: mitotane and adriamycin in patients with advanced adrenocortical carcinoma / R.A. Decker [et al.]

// Surgery. – 1991. – Vol. 110, №6. – P. 1006-1013.

88. Deckers, S. Peritoneal carcinomatosis following laparoscopic resection of an adrenocortical tumor causing primary hyperaldosteronism / S. Deckers [et al.] // Horm. Res. – 1999. – Vol. 52, №2. – P. 97-100.

89. Deutsche Nebennieren-Karzinom-Register [Электронный ресурс]. – Режим доступа: http://www.nebennierenkarzinom.ukw.de – Заглавие с экрана. – (Дата обращения: 14.04.2014).

90. Doghman, M. Regulation of insulin-like growth factor-mammalian target of rapamycin signaling by microRNA in childhood adrenocortical tumors / M. Doghman [et al.] // Cancer Res. – 2010. – Vol. 70, №11. – P. 4666-4675.

91. Dong, D. Surgical management and clinical prognosis of adrenocortical carcinoma / D. Dong [et al.] // Urol. Int. – 2012. – Vol. 88, №4. – P. 400-404.

92. Durivage, H.J. Prevention and Management of Toxicities Associated With Antineoplastic Drugs / H.J. Durivage, N.L. Burnham // J. Pharm. Pract. – 1991. – Vol. 4, №1. – P. 27-48.

93. Edge, S. AJCC Cancer Staging Manual / S. Edge [et al.]. – 7th ed. – New- York: Springer, 2010. – 649 p.

94. Eriksson, B. Positron emission tomography in neuroendocrine tumours / B. Eriksson [et al.] // Ital. J. Gastroenterol. Hepatol. – 1999. – Vol. 31. – S. 167-171 (Suppl. 2).

95. Faria, J.F. Adrenal masses: characterization with in vivo proton MR spectroscopy – initial experience / J.F. Faria [et al.] // Radiology. – 2007. – Vol. 245,

№3. – P. 788-797.

96. Fassina, A.S. Fine needle aspiration cytology (FNAC) of adrenal masses / A.S. Fassina, S. Borsato, U. Fedeli // Cytopathology. – 2000. – Vol. 11, №5. – P. 302-311.

97. Fassnacht, M. Adrenal tumors: how to establish malignancy? / M. Fassnacht,

W. Kenn, B. Allolio // J. Endocrinol. Invest. – 2004. – Vol. 27, №4. – P. 387-399.

98. Fassnacht, M. Adrenocortical carcinoma: a clinician’s update / M. Fassnacht [et al.] // Nat. Rev. Endocrinol. – 2011. – Vol. 7, №6. – P. 323-335.

99. Fassnacht, M. Clinical management of adrenocortical carcinoma / M. Fassnacht, B. Allolio // Best Pract. Res. Clin. Endocrinol. Metab. – 2009. – Vol. 23,

№2. – P. 273-289.

100. Fassnacht, M. Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma / M. Fassnacht [et al.] // J. Clin. Endocrinol. Metab. – 2006. – Vol. 91, №11. – P. 4501-4504.

101. Fassnacht, M. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification / M. Fassnacht [et al.] // Cancer. – 2009. – Vol. 115,

№2. – P. 243-250.

102. Fenske, W. Glucose transporter GLUT1 expression is an stage-independent predictor of clinical outcome in adrenocortical carcinoma / W. Fenske [et al.] // Endocr. Relat. Cancer. – 2009. – Vol. 16, №3. – P. 919-928.

103. Fischer, A.H. Incorporating pathologists’ criteria of malignancy into the evolutionary model for cancer development / A.H. Fischer, K.A. Young, R.A. DeLellis // J. Cell. Biochem. – 2004. – Vol. 93, №1. – P. 28-36.

104. Fuhrman, S.A. Prognostic significance of morphologic parameters in renal cell carcinoma / S.A. Fuhrman, L.C. Lasky, C. Limas // Am. J. Surg. Pathol. – 1982. – Vol. 6, №7. – P. 655-663.

105. Gaujoux, S. Recommendation for standardized surgical management of primary adrenocortical carcinoma / S. Gaujoux, M.F. Brennan // Surgery. – 2012. – Vol. 152, №1. – P. 123-132.

106. Gicquel, C. Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors / C. Gicquel [et al.] // Cancer Res. – 2001. – Vol. 61, №18. – P. 6762-6767.

107. Gicquel, C. Rearrangements at the 11p15 locus and overexpression of insulin- like growth factor-II gene in sporadic adrenocortical tumors / C. Gicquel [et al.] // J. Clin. Endocrinol. Metab. – 1994. – Vol. 78, №6. – P. 1444-1453.

108. Giordano, T.J. Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis / T.J. Giordano [et al.] // Am. J. Pathol. – 2003. – Vol. 162, №2. – P. 521-531.

109. Giordano, T.J. Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling / T.J. Giordano [et al.] // Clin. Cancer Res. – 2009.

– Vol. 15, №2. – P. 668-676.

110. Golden, S.H. Clinical review: Prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review / S.H. Golden [et al.] // J. Clin. Endocrinol. Metab. – 2009. – Vol. 94, №6. – P. 1853-1878.

111. Gomez-Rivera, F. Adrenocortical carcinoma: a single institution experience / F. Gomez-Rivera [et al.] // Am. Surg. – 2005. – Vol. 71, №1. – P. 90-94.

112. Gonzalez, R.J. Laparoscopic resection of adrenal cortical carcinoma: a cautionary note / R.J. Gonzalez [et al.] // Surgery. – 2005. – Vol. 138, №6. – P. 1078- 1085.

113. Groussin, L. 18F-Fluorodeoxyglucose positron emission tomography for the diagnosis of adrenocortical tumors: a prospective study in 77 operated patients / L. Groussin [et al.] // J. Clin. Endocrinol. Metab. – 2009. – Vol. 94, №5. – P. 1713- 1722.

114. Gumbs, A.A. Laparoscopic adrenalectomy / A.A. Gumbs, M. Gagner // Best Pract. Res. Clin. Endocrinol. Metab. – 2006. – Vol. 20, №3. – P. 483-499.

115. Guyatt, G.H. Measuring health status: what are the necessary measurement properties? / G.H. Guyatt, B. Kirshner, R. Jaeschke // J. Clin. Epidemiol. – 1992. – Vol. 45, №12. – P. 1341-1345.

116. Hahner, S. [123I]Iodometomidate for molecular imaging of adrenocortical cytochrome P450 family 11B enzymes / S. Hahner [et al.] // J. Clin. Endocrinol. Metab. – 2008. – Vol. 93, №6. – P. 2358-2365.

117. Haluska, P. Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma / P. Haluska [et al.] // Cancer Chemother. Pharmacol. – 2010. – Vol. 65,

№4. – P. 765-773.

118. Hedican, S.P. Adrenocortical carcinoma with intracaval extension / S.P. Hedican, F.F. Marshall // J. Urol. – 1997. – Vol. 158, №6. – P. 2056-2061.

119. Heinz-Peer, G. Imaging of adrenal masses / G. Heinz-Peer, M. Memarsadeghi, B. Niederle // Curr. Opin. Urol. – 2007. – Vol. 17, №1. – P. 32-28.

120. Hennings, J. [11C]metomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings / J. Hennings [et al.] // J. Clin. Endocrinol. Metab. – 2006. – Vol. 91, №4. – P. 1410-1414.

121. Herve, M.-A. Overexpression of vascular endothelial growth factor 189 in breast cancer cells leads to delayed tumor uptake with dilated intratumoral vessels / M.-A. Herve [et al.] // Am. J. Pathol. – 2008. – Vol. 172, №1. – P. 167-178.

122. Hisada, M. Multiple primary cancers in families with Li-Fraumeni syndrome / M. Hisada [et al.] // J. Natl. Cancer Inst. – 1998. – Vol. 90, №8. – P. 606-611.

123. Honigschnabl, S. How accurate is MR imaging in characterisation of adrenal masses: update of a long-term study / S. Honigschnabl [et al.] // Eur. J. Radiol. – 2002. – Vol. 41, №2. – P. 113-122.

124. Hunt, R.H. Quality of Life – the challenges ahead / R.H. Hunt // Scand. J. Gastroenterol. Suppl. – 1993. – Vol. 199. – P. 2-4.

125. Hurwitz, H. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer / H. Hurwitz [et al.] // N. Engl. J. Med. – 2004. – Vol. 350, №23. – P. 2335-2342.

126. Hussain, H.K. MR imaging of the adrenal glands / H.K. Hussain, M. Korobkin

// Magn. Reson. Imaging Clin. N. Am. – 2004. – Vol. 12, №3. – P. 515-544.

127. Hutter, A.M. Adrenal cortical carcinoma. Results of treatment with o,p’DDD in 138 patients / A.M. Hutter, D.E. Kayhoe // Am. J. Med. – 1966. – Vol. 41, №4. – P. 581-592.

128. Icard, P. Adrenocortical carcinoma in surgically treated patients: a retrospective study on 156 cases by the French Association of Endocrine Surgery / P. Icard [et al.] // Surgery. – 1992. – Vol. 112, №6. – P. 972-979.

129. Icard, P. Adrenocortical carcinomas: surgical trends and results of a 253- patient series from the French Association of Endocrine Surgeons study group / P. Icard [et al.] // World J. Surg. – 2001. – Vol. 25, №7. – P. 891-897.

130. Ilias, I. The optimal imaging of adrenal tumours: a comparison of different methods / I. Ilias [et al.] // Endocr. Relat. Cancer. – 2007. – Vol. 14, №3. – P. 587- 599.

131. Ito, Y. Efficacy of single-voided urine metanephrine and normetanephrine assay for diagnosing pheochromocytoma / Y. Ito [et al.] // World J. Surg. – 1998. – Vol. 22, №7. – P. 684-688.

132. Johnson, P.T. Adrenal mass imaging with multidetector CT: pathologic conditions, pearls, and pitfalls / P.T. Johnson, K.M. Horton, E.K. Fishman // Radiographics. – 2009. – Vol. 29, №5. – P. 1333-1351.

133. Kamat, A.A. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer / A.A. Kamat [et al.] // Clin. Cancer Res. – 2007.

– Vol. 13, №24. – P. 7487-7495.

134. Kebebew, E. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? / E. Kebebew [et al.] // World J. Surg. – 2006. – Vol. 30, №5. – P. 872-878.

135. Kendrick, M.L. Adrenocortical carcinoma: surgical progress or status quo? / M.L. Kendrick [et al.] // Arch. Surg. – 2001. – Vol. 136, №5. – P. 543-549.

136. Keskin, S. Adrenocortical carcinoma: clinicopathological features, prognostic factors and outcome / S. Keskin, F. Tas, S. Vatansever // Urol. Int. – 2013. – Vol. 90,

№4. – P. 435-438.

137. Khan, T.S. 11C-metomidate PET imaging of adrenocortical cancer / T.S. Khan [et al.] // Eur. J. Nucl. Med. Mol. Imaging. – 2003. – Vol. 30, №3. – P. 403-410.

138. Khan, T.S. Streptozocin and o,p’DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use / T.S. Khan [et al.] // Ann. Oncol. – 2000. – Vol. 11, №10. – P. 1281-1287.

139. Khan, T.S. Vincristine, cisplatin, teniposide, and cyclophosphamide combination in the treatment of recurrent or metastatic adrenocortical cancer / T.S. Khan [et al.] // Med. Oncol. – 2004. – Vol. 21, №2. – P. 167-177.

140. Kiiveri, S. Transcription factors GATA-6, SF-1, and cell proliferation in human adrenocortical tumors / S. Kiiveri [et al.] // Mol. Cell. Endocrinol. – 2005. – Vol. 233, №1-2. – P. 47-56.

141. Kjellman, M. Genotyping of adrenocortical tumors: very frequent deletions of the MEN1 locus in 11q13 and of a 1-centimorgan region in 2p16 / M. Kjellman [et al.] // J. Clin. Endocrinol. Metab. – 1999. – Vol. 84, №2. – P. 730-735.

142. Kolomecki, K. Usefulness of VEGF, MMP-2, MMP-3 and TIMP-2 serum level evaluation in patients with adrenal tumours / K. Kolomecki [et al.] // Endocr. Regul. – 2001. – Vol. 35, №1. – P. 9-16.

143. Korobkin, M. Adrenal imaging / M. Korobkin, I.R. Francis // Semin. Ultrasound. CT. MR. – 1995. – Vol. 16, №4. – P. 317-330.

144. Korobkin, M. Characterization of adrenal masses with chemical shift and gadolinium-enhanced MR imaging / M. Korobkin [et al.] // Radiology. – 1995. – Vol. 197, №2. – P. 411-418с.

145. Korobkin, M. CT time-attenuation washout curves of adrenal adenomas and nonadenomas / M. Korobkin [et al.] // AJR. Am. J. Roentgenol. – 1998. – Vol. 170,

№3. – P. 747-752.

146. Koschker, A.-C. Adrenocortical carcinoma – improving patient care by establishing new structures / A.-C. Koschker [et al.] // Exp. Clin. Endocrinol. Diabetes – 2006. – Vol. 114, №2. – P. 45-51.

147. Lafemina, J. Adrenocortical carcinoma: past, present, and future / J. Lafemina, M.F. Brennan // J. Surg. Oncol. – 2012. – Vol. 106, №5. – P. 586-594.

148. Leboulleux, S. Adrenocortical carcinoma: is the surgical approach a risk factor of peritoneal carcinomatosis? / S. Leboulleux [et al.] // Eur. J. Endocrinol. – 2010. – Vol. 162, №6. – P. 1147-1153.

149. Leboulleux, S. Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography / S. Leboulleux [et al.] // J. Clin. Endocrinol. Metab. – 2006. – Vol. 91, №3. – P. 920-925.

150. Lee, J. Surgical management, DNA content, and patient survival in adrenal cortical carcinoma / J. Lee [et al.] // Surgery. – 1995. – Vol. 118, №6. – P. 1090- 1098.

151. Lehmann, T. The molecular basis of adrenocortical cancer / T. Lehmann, T. Wrzesinski // Cancer Genet. – 2012. – Vol. 205, №4. – P. 131-137.

152. Linos, D.A. Adrenal Glands: Diagnostic Aspects and Surgical Therapy / D.A. Linos, J.A. van Heerden. – Berlin: Springer, 2005. – 362 p.

153. Logan-Collins, J.M. VEGF expression predicts survival in patients with peritoneal surface metastases from mucinous adenocarcinoma of the appendix and colon / J.M. Logan-Collins [et al.] // Ann. Surg. Oncol. – 2008. – Vol. 15, №3. – P. 738-744.

154. Lubitz, J.A. Mitotane use in inoperable adrenal cortical carcinoma / J.A. Lubitz, L. Freeman, R. Okun // JAMA. – 1973. – Vol. 223, №10. – P. 1109-1112.

155. Lughezzani, G. The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer- staging system: a North American validation / G. Lughezzani [et al.] // Eur. J. Cancer. – 2010. – Vol. 46, №4. – P. 713-719.

156. Lumachi, F. Role and cost-effectiveness of adrenal imaging and image-guided FNA cytology in the management of incidentally discovered adrenal tumours / F. Lumachi [et al.] // Anticancer Res. – 2005. – Vol. 25, №6C. – P. 4559-4562.

157. Luton, J.P. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy / J.P. Luton [et al.] // N. Engl. J. Med. – 1990. – Vol. 322, №17. – P. 1195-1201.

158. Macfarlane, D. Cancer of the adrenal cortex; the natural history, prognosis and treatment in a study of fifty-five cases / D. Macfarlane // Ann. R. Coll. Surg. Engl. – 1958. – Vol. 23, №3. – P. 155-166.

159. Mackie, G.C. Use of [18F]fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma / G.C. Mackie [et al.] // J. Clin. Endocrinol. Metab. – 2006. – Vol. 91, №7. – P. 2665-2671.

160. Madoux, F. Potent, selective and cell penetrant inhibitors of SF-1 by functional ultra-high-throughput screening / F. Madoux [et al.] // Mol. Pharmacol. – 2008. – Vol. 73, №6. – P. 1776-1784.

161. Maher, E.R. Beckwith-Wiedemann syndrome: imprinting in clusters revisited / E.R. Maher, W. Reik // J. Clin. Invest. – 2000. – Vol. 105, №3. – P. 247-252.

162. McCauley, L.R. Laparoscopic radical adrenalectomy for cancer: long-term outcomes / L.R. McCauley, M.M. Nguyen // Curr. Opin. Urol. – 2008. – Vol. 18,

№2. – P. 134-138.

163. Metser, U. 18F-FDG PET/CT in the evaluation of adrenal masses / U. Metser [et al.] // J. Nucl. Med. – 2006. – Vol. 47, №1. – P. 32-37.

164. Meyer, A. Long-term follow-up after adrenalectomy for primary aldosteronism

/ A. Meyer, G. Brabant, M. Behrend // World J. Surg. – 2005. – Vol. 29, №2. – P. 155-159.

165. Miller, B.S. Laparoscopic resection is inappropriate in patients with known or suspected adrenocortical carcinoma / B.S. Miller [et al.] // World J. Surg. – 2010. – Vol. 34, №6. – P. 1380-1385.

166. Miller, B.S. Proposal for modification of the ENSAT staging system for adrenocortical carcinoma using tumor grade / B.S. Miller [et al.] // Langenbecks. Arch. Surg. – 2010. – Vol. 395, №7. – P. 955-961.

167. Miyazono, N. Transcatheter arterial renal and adrenal embolization with iohexol-ethanol solutions. Animal experimental study and clinical application / N. Miyazono [et al.] // Invest. Radiol. – 1996. – Vol. 31, №12. – P. 755-760.

168. Moinzadeh, A. Laparoscopic radical adrenalectomy for malignancy in 31 patients / A. Moinzadeh, I.S. Gill // J. Urol. – 2005. – Vol. 173, №2. – P. 519-525.

169. Morimoto, R. Immunohistochemistry of a proliferation marker Ki67/MIB1 in adrenocortical carcinomas: Ki67/MIB1 labeling index is a predictor for recurrence of adrenocortical carcinomas / R. Morimoto [et al.] // Endocr. J. – 2008. – Vol. 55, №1.

– P. 49-55.

170. Mulatero, P. Diagnosis of primary aldosteronism: from screening to subtype differentiation / P. Mulatero [et al.] // Trends Endocrinol. Metab. – 2005. – Vol. 16,

№3. – P. 114-119.

171. Murphy, M.M. Trends in adrenalectomy: a recent national review / M.M. Murphy [et al.] // Surg. Endosc. – 2010. – Vol. 24, №10. – P. 2518-2526.

172. Nader, S. Adrenal cortical carcinoma. A study of 77 cases / S. Nader [et al.] // Cancer. – 1983. – Vol. 52, №4. – P. 707-711.

173. Naughton, M.J. The case for domains of function in quality of life assessment /

M.J. Naughton, S.A. Shumaker // Qual. Life Res. – 2003. – Vol. 12 – P. 73-80 (Suppl. 1).

174. Ng, L. Adrenocortical carcinoma: diagnosis, evaluation and treatment / L. Ng, J.M. Libertino // J. Urol. – 2003. – Vol. 169, №1. – P. 5-11.

175. Norton, J. Adrenal tumors / J. Norton // Cancer: principles and practice of oncology / ed. V.T. DeVita, S. Hellman, S.A. Rosenberg. – 5th ed. – Philadelphia, PA: Lippincott-Raven, 1997. – P. 1659-1677.

176. Papotti, M. The Weiss score and beyond – histopathology for adrenocortical carcinoma / M. Papotti [et al.] // Horm. Cancer. – 2011. – Vol. 2, №6. – P. 333-340.

177. Parker, K.L. Steroidogenic factor 1: a key determinant of endocrine development and function / K.L. Parker, B.P. Schimmer // Endocr. Rev. – 1997. – Vol. 18, №3. – P. 361-377.

178. Pena, C.S. Characterization of indeterminate (lipid-poor) adrenal masses: use of washout characteristics at contrast-enhanced CT / C.S. Pena [et al.] // Radiology. – 2000. – Vol. 217, №3. – P. 798-802.

179. Pianovski, M.A.D. SF-1 overexpression in childhood adrenocortical tumours /

M.A.D. Pianovski [et al.] // Eur. J. Cancer. – 2006. – Vol. 42, №8. – P. 1040-1043.

180. Pinto, E.M. Founder effect for the highly prevalent R337H mutation of tumor suppressor p53 in Brazilian patients with adrenocortical tumors / E.M. Pinto [et al.] // Arq. Bras. Endocrinol. Metab. – 2004. – Vol. 48, №5. – P. 647-650.

181. Pohlink, C. Does tumor heterogeneity limit the use of the Weiss criteria in the evaluation of adrenocortical tumors? / C. Pohlink [et al.] // J. Endocrinol. Invest. – 2004. – Vol. 27, №6. – P. 565-569.

182. Porpiglia, F. Retrospective evaluation of the outcome of open versus laparoscopic adrenalectomy for stage I and II adrenocortical cancer / F. Porpiglia [et al.] // Eur. Urol. – 2010. – Vol. 57, №5. – P. 873-878.

183. Portnov, B.A. Exploratory analysis of potential risk factors of a rare disease: spatial distribution of adrenocortical carcinoma in Israel as a case study / B.A. Portnov [et al.] // Sci. Total Environ. – 2009. – Vol. 407, №5. – P. 1738-1743.

184. Ramos-De la Medina, A. Adrenocortical carcinoma presenting as a retroperitoneal abscess: an unusual presentation of a rare tumor / A. Ramos-De la Medina, F.G. Que // Endocr. Pract. – 2007. – Vol. 13, №5. – P. 567-570.

185. Rhim, H. Radiofrequency thermal ablation of abdominal tumors: lessons learned from complications / H. Rhim [et al.] // Radiographics. – 2004. – Vol. 24,

№1. – P. 41-52.

186. Ribeiro, R.C. An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma / R.C. Ribeiro [et al.] // Proc. Natl. Acad. Sci. U. S. A. – 2001. – Vol. 98, №16. – P. 9330-9335.

187. Rolleston, H.D. Primary Malignant Disease of the Suprarenal Bodies / H.D. Rolleston, H.W.J. Marks // Am. J. Med. Sci. – 1898. – Vol. CXVI. – P. 383-404.

188. Roman, S. Adrenocortical carcinoma / S. Roman // Curr. Opin. Oncol. – 2006.

– Vol. 18, №1. – P. 36-42.

189. Rossi, G.P. Cardiac consequences of aldosterone excess in human hypertension / G.P. Rossi // Am. J. Hypertens. – 2006. – Vol. 19, №1. – P. 10-12.

190. Sabolch, A. Adjuvant and definitive radiotherapy for adrenocortical carcinoma

/ A. Sabolch [et al.] // Int. J. Radiat. Oncol. Biol. Phys. – 2011. – Vol. 80, №5. – P. 1477-1484.

191. Saeger, W. High diagnostic accuracy of adrenal core biopsy: results of the German and Austrian adrenal network multicenter trial in 220 consecutive patients / W. Saeger [et al.] // Hum. Pathol. – 2003. – Vol. 34, №2. – P. 180-186.

192. Sartorius, N. Trans-cultural research on depression / N. Sartorius // Rev. Med. Suisse Romande. – 1987. – Vol. 107, №12. – P. 1019-1023.

193. Sasano, H. Recent advances in histopathology and immunohistochemistry of adrenocortical carcinoma / H. Sasano, T. Suzuki, T. Moriya // Endocr. Pathol. – 2006. – Vol. 17, №4. – P. 345-354.

194. Sasano, H. Transcription factor adrenal 4 binding protein as a marker of adrenocortical malignancy / H. Sasano [et al.] // Hum. Pathol. – 1995. – Vol. 26,

№10. – P. 1154-1156.

195. Saunders, B.D. Laparoscopic adrenalectomy for malignant disease / B.D. Saunders, G.M. Doherty // Lancet Oncol. – 2004. – Vol. 5, №12. – P. 718-726.

196. Schlumberger, M. 5-Fluorouracil, doxorubicin, and cisplatin as treatment for adrenal cortical carcinoma / M. Schlumberger [et al.] // Cancer. – 1991. – Vol. 67,

№12. – P. 2997-3000.

197. Schmitt, A. IGFII and MIB1 immunohistochemistry is helpful for the differentiation of benign from malignant adrenocortical tumours / A. Schmitt [et al.]

// Histopathology. – 2006. – Vol. 49, №3. – P. 298-307.

198. Schreinemakers, J.M.J. The adrenocortical carcinoma, a tumour of wide clinical diversity / J.M.J. Schreinemakers [et al.] // Ned. Tijdschr. Geneeskd. – 2004.

– Vol. 148, №43. – P. 2109-2113.

199. Schteingart, D.E. Management of patients with adrenal cancer: recommendations of an international consensus conference / D.E. Schteingart [et al.]

// Endocr. Relat. Cancer. – 2005. – Vol. 12, №3. – P. 667-680.

200. Schulick, R.D. Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma / R.D. Schulick, M.F. Brennan // Ann. Surg. Oncol. – 1999. – Vol. 6, №8. – P. 719-726.

201. Schulte, K.M. Complete sequencing and messenger ribonucleic acid expression analysis of the MEN I gene in adrenal cancer / K.M. Schulte [et al.] // J. Clin. Endocrinol. Metab. – 2000. – Vol. 85, №1. – P. 441-448.

202. Schulte, K.M. MEN I gene mutations in sporadic adrenal adenomas / K.M. Schulte [et al.] // Hum. Genet. – 1999. – Vol. 105, №6. – P. 603-610.

203. Seccia, T.M. Aldosterone-producing adrenocortical carcinoma: an unusual cause of Conn’s syndrome with an ominous clinical course / T.M. Seccia [et al.] // Endocr. Relat. Cancer. – 2005. – Vol. 12, №1. – P. 149-159.

204. SEER Cancer Statistics Review 1975-2010 [Электронный ресурс] / National Cancer Institute. – Режим доступа: http://www.seer.cancer.gov/archive/csr/1975_2010/ – Заглавие с экрана. – (Дата обращения: 14.11.2014).

205. Skogseid, B. Clinical and genetic features of adrenocortical lesions in multiple endocrine neoplasia type 1 / B. Skogseid [et al.] // J. Clin. Endocrinol. Metab. – 1992.

– Vol. 75, №1. – P. 76-81.

206. Slater, E.P. Analysis by cDNA microarrays of gene expression patterns of human adrenocortical tumors / E.P. Slater [et al.] // Eur. J. Endocrinol. – 2006. – Vol. 154, №4. – P. 587-598.

207. Solcia, E. Morphological, molecular, and prognostic aspects of gastric endocrine tumors / E. Solcia [et al.] // Microsc. Res. Tech. – 2000. – Vol. 48, №6. – P. 339-348.

208. Soon, P.S.H. Loss of heterozygosity of 17p13, with possible involvement of ACADVL and ALOX15B, in the pathogenesis of adrenocortical tumors / P. S.H. Soon [et al.] // Ann. Surg. – 2008. – Vol. 247, №1. – P. 157-164.

209. Stojadinovic, A. Adrenocortical carcinoma: clinical, morphologic, and molecular characterization / A. Stojadinovic [et al.] // J. Clin. Oncol. – 2002. – Vol. 20, №4. – P. 941-950.

210. Sullivan, M. Adrenal cortical carcinoma / M. Sullivan, M. Boileau, C. Hodges

// J. Urol. – 1978. – Vol. 120, №6. – P. 660-665.

211. Surgical endocrinology / ed. B. Skogseid, G.M. Doherty. – Philadelphia, PA: Lippincott Williams & Wilkins, 2001. – 640 p.

212. Suyama, K. Spontaneous rupture of adrenocortical carcinoma / K. Suyama [et al.] // Am. J. Surg. – 2007. – Vol. 194, №1. – P. 77-78.

213. Suzuki, K. Complications of laparoscopic adrenalectomy in 75 patients treated by the same surgeon / K. Suzuki, T. Ushiyama, H. Ihara, S. Kageyama, S. Mugiya, K. Fujita // Eur. Urol. – 1999. – Vol. 36, №1. – P. 40-47.

214. Szolar, D.H. Adrenocortical carcinomas and adrenal pheochromocytomas: mass and enhancement loss evaluation at delayed contrast-enhanced CT / D.H. Szolar [et al.] // Radiology. – 2005. – Vol. 234, №2. – P. 479-485.

215. Tatic, S. Pheochromocytoma – pathohistologic and immunohistochemical aspects / S. Tatic [et al.] // Srp. Arh. Celok. Lek. – 2002. – Vol. 130. – P. 7-13 (Suppl.).

216. Terzolo, M. Adjuvant mitotane treatment for adrenocortical carcinoma / M. Terzolo [et al.] // N. Engl. J. Med. – 2007. – Vol. 356, №23. – P. 2372-2380.

217. Tsushima, Y. Adrenal masses: differentiation with chemical shift, fast low- angle shot MR imaging / Y. Tsushima, H. Ishizaka, M. Matsumoto // Radiology. – 1993. – Vol. 186, №3. – P. 705-709.

218. Tucci, S. The impact of tumor stage on prognosis in children with adrenocortical carcinoma / S. Tucci [et al.] // J. Urol. – 2005. – Vol. 174, №6. – P. 2338-2342.

219. van Slooten, H. CAP (cyclophosphamide, doxorubicin, and cisplatin) regimen in adrenal cortical carcinoma / H. van Slooten, A.T. van Oosterom // Cancer. Treat. Rep. – 1983. – Vol. 67, №4. – P. 377-379.

220. van Slooten, H. Morphologic characteristics of benign and malignant adrenocortical tumors / H. van Slooten [et al.] // Cancer. – 1985. – Vol. 55, №4. – P. 766-773.

221. van Slooten, H. The treatment of adrenocortical carcinoma with o,p’-DDD: prognostic implications of serum level monitoring / H. van Slooten [et al.] // Eur. J. Cancer Clin. Oncol. – 1984. – Vol. 20, №1. – P. 47-53.

222. Vassilopoulou-Sellin, R. Adrenocortical carcinoma. Clinical outcome at the end of the 20th century / R. Vassilopoulou-Sellin, P.N. Schultz // Cancer. – 2001. – Vol. 92, №5. – P. 1113-1121.

223. Vassilopoulou-Sellin, R. Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer / R. Vassilopoulou-Sellin [et al.] // Cancer. – 1993. – Vol. 71, №10. – P. 3119-3123.

224. Venkatesh, S. Adrenal cortical carcinoma / S. Venkatesh [et al.] // Cancer. – 1989. – Vol. 64, №3. – P. 765-769.

225. Vincent, J.M. Computed tomography of diffuse, non-metastatic enlargement of the adrenal glands in patients with malignant disease / J.M. Vincent [et al.] // Clin. Radiol. – 1994. – Vol. 49, №7. – P. 456-460.

226. Volante, M. Matrix metalloproteinase type 2 expression in malignant adrenocortical tumors: Diagnostic and prognostic significance in a series of 50 adrenocortical carcinomas / M. Volante [et al.] // Mod. Pathol. – 2006. – Vol. 19,

№12. – P. 1563-1569.

an update / M. Volante [et al.] // J. Clin. Pathol. – 2008. – Vol. 61, №7. – P. 787-793.

228. Wajchenberg, B.L. Adrenocortical carcinoma: clinical and laboratory observations / B.L. Wajchenberg [et al.] // Cancer. – 2000. – Vol. 88, №4. – P. 711- 736.

229. Waldmann, J. Adrenal involvement in multiple endocrine neoplasia type 1: results of 7 years prospective screening / J. Waldmann [et al.] // Langenbecks. Arch. Surg. – 2007. – Vol. 392, №4. – P. 437-443.

230. Ware, J.E. Measuring patients’ views: the optimum outcome measure / J.E. Ware // BMJ. – 1993. – Vol. 306, №6890. – P. 1429-1430.

231. Watson, W.L. Retrospective baseline measurement of self-reported health status and health-related quality of life versus population norms in the evaluation of post-injury losses / W.L. Watson, J. Ozanne-Smith, J. Richardson // Inj. Prev. – 2007.

– Vol. 13, №1. – P. 45-50.

232. Weiss, L.M. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors / L.M. Weiss // Am. J. Surg. Pathol. – 1984.

– Vol. 8, №3. – P. 163-169.

233. Weiss, L.M. Pathologic features of prognostic significance in adrenocortical carcinoma / L.M. Weiss, L.J. Medeiros, A.L. Vickery // Am. J. Surg. Pathol. – 1989.

– Vol. 13, №3. – P. 202-206.

234. Williamson, S.K. Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study / S.K. Williamson [et al.] // Cancer. – 2000. – Vol. 88, №5. – P. 1159-1165.

235. Wood, B.J. Radiofrequency ablation of adrenal tumors and adrenocortical carcinoma metastases / B.J. Wood [et al.] // Cancer. – 2003. – Vol. 97, №3. – P. 554- 560.

236. Wooten, M.D. Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature / M.D. Wooten, D.K. King // Cancer. – 1993.

– Vol. 72, №11. – P. 3145-3155.

al.] // J. Natl. Cancer Inst. – 1989. – Vol. 81, №7. – P. 518-523.